South Asian Journal of Cancer

ORIGINAL ARTICLE: GYNAECOLOGICAL CANCERS
Year
: 2020  |  Volume : 9  |  Issue : 1  |  Page : 30--33

Does preoperative CA-125 cutoff value and percent reduction in CA-125 levels correlate with surgical and survival outcome after neoadjuvant chemotherapy in patients with advanced-stage ovarian cancer? – Our experience from a tertiary cancer institute


Monisha Gupta, Shilpa Mukesh Patel, Ruchi Arora, Rajneesh Tiwari, Pariseema Dave, Ava Desai, Meeta Mankad 
 Department of Gynecology Oncology, Gujarat Cancer and Research Institute, Ahmedabad, Gujarat, India

Correspondence Address:
Dr. Monisha Gupta
Department of Gynecology Oncology, Gujarat Cancer and Research Institute, Ahmedabad, Gujarat
India

Aim: The aim of the study is to evaluate percent fall in CA-125 levels after neoadjuvant chemotherapy (NAC) and preoperative CA-125 value to predict surgical and survival outcomes in women with advanced-stage epithelial ovarian cancer (EOC). Methods: A retrospective review of 406 women receiving NAC for advanced-stage EOC from January 2012 to July 2015 was conducted. Data were collected for demography, radiographic profile, CA-125 levels before and after NAC, chemotherapy, and surgicopathological information. Percent fall in CA-125 was categorized into two groups: <95% (R < 95) and >95% (R > 95) fall from prechemotherapy to preoperative levels. Similarly, women were also categorized using preoperative CA-125 levels of <100 and >100 U/ml. A subset of women from January 2012 to December 2013 was followed to June 2015 for evidence of any recurrence to determine survival outcomes. Results: About 56% women had R > 95 and 44% had R < 95. As compared to R < 95, R > 95 group was more likely to have complete cytoreduction (P = 0.00). Furthermore, women with R > 95 had significant better progression-free survival (PFS) as compared to women with R < 95 (P = 0.009) but no difference in overall survival (OS) (P = 0.28). Women with preoperative CA-125 <100 had significant higher number of complete cytoreduction (55% vs. 40%; P = 0.00) and were associated with both PFS (P = 0.007) and OS benefit (P = 0.02). Conclusion: Our data showed that >95% fall in CA-125 and an absolute preoperative CA-125 value of <100 U/ml is associated with better surgical and survival outcome in women with advanced EOC. These data are important in patient counseling and treatment planning.


How to cite this article:
Gupta M, Patel SM, Arora R, Tiwari R, Dave P, Desai A, Mankad M. Does preoperative CA-125 cutoff value and percent reduction in CA-125 levels correlate with surgical and survival outcome after neoadjuvant chemotherapy in patients with advanced-stage ovarian cancer? – Our experience from a tertiary cancer institute.South Asian J Cancer 2020;9:30-33


How to cite this URL:
Gupta M, Patel SM, Arora R, Tiwari R, Dave P, Desai A, Mankad M. Does preoperative CA-125 cutoff value and percent reduction in CA-125 levels correlate with surgical and survival outcome after neoadjuvant chemotherapy in patients with advanced-stage ovarian cancer? – Our experience from a tertiary cancer institute. South Asian J Cancer [serial online] 2020 [cited 2020 Feb 20 ];9:30-33
Available from: http://journal.sajc.org/article.asp?issn=2278-330X;year=2020;volume=9;issue=1;spage=30;epage=33;aulast=Gupta;type=0